Immunogenicity of hepatitis B vaccine in preterm infants

Arch Dis Child Fetal Neonatal Ed. 1998 Nov;79(3):F206-8. doi: 10.1136/fn.79.3.f206.

Abstract

Aim: To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth.

Method: The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test.

Results: A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p = NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p < 0.03).

Conclusion: Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.

MeSH terms

  • Antibody Formation
  • Case-Control Studies
  • Chi-Square Distribution
  • Female
  • Hepatitis B / prevention & control*
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Immunization Schedule
  • Infant
  • Infant, Newborn
  • Infant, Premature / immunology*
  • Male
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / immunology*

Substances

  • Engerix-B
  • Hepatitis B Vaccines
  • Vaccines, Synthetic